Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2016

View Archived Issues

FDA approves blood-based companion diagnostic for Tagrisso

Cempra announces encouraging interim data from phase II trial of solithromycin in NASH

Micatrio approved in Japan for hypertension

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Safety and efficacy of durvalumab in patients with advanced urothelial bladder cancer

Combination of routine biochemical markers improves the management of patients with MDD

Bayer Pharma patents prostanoid FP antagonists

Bayer Pharma discloses coagulation factor XIa and kallikrein inhibitors

Roche describes mGlu4 receptor positive allosteric modulators

Cellectar Biosciences reports positive data on phase I trial of CLR-131

Hetero Research Foundation develops antiviral agents

Genentech and Roche present JAK1 inhibitors

Catabasis and Sarepta enter joint DMD research collaboration

EMA accepts and validates masitinib MAA for ALS

Boehringer Ingelheim and Sarah Cannon Institute enter collaboration for cancer drug development

Reducing off-target NELL-1 effects

Celgene exercises option to obtain ex-U.S. rights to Abide's ABX-1431

Bill & Melinda Gates Foundation gives grant to Sirenas

Cognition Therapeutics receives grant from Michael J. Fox Foundation for research in Parkinson's

Novel T-type calcium channel blockers show analgesic effects in vivo

Allergan licenses MEDI-2070 rights from MedImmune

FDA completes IND review for phase II study of nilotinib in patients Alzheimer's disease

Promising data from first phase III trial of Cimzia in moderate to severe chronic plaque psoriasis

Regeneron reports topline data from phase II trial of aflibercept/rinucumab in wet AMD

Glecaprevir/pibrentasvir investigational HCV regimen receives FDA breakthrough therapy designation

Truberzi approved in E.U. for IBS-D

Proveca's Sialanar approved in Europe for sialorrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...